A subsequent inquiry revealed that neither Gelsinger nor his family had been told of similar reactions in animal trials, his liver test results should have made him ineligible for the study and poor results of other gene-therapy volunteers had not been made available to the regulatory body at the FDA.
These patients became ineligible for the study.
Participants unable to give written or verbal informed consent or taking acyclovir or ganciclovir were ineligible for the study.
Women with multifetal gestations were ineligible for the study if they also had diabetes mellitus, chronic hypertension, or proteinuria as defined above, as were women with a history of preeclampsia and current proteinuria.
Women with multi-fetal gestations were ineligible for the study if they also had diabetes mellitus, chronic hypertension, or proteinuria as defined above, as were women with a history of preeclampsia and current proteinuria.
Of these, 63 patients were participants of phase III trials and were ineligible for the study.
Three tumors were removed because they became ineligible for the study.
Therefore, according to the PedsQL™ 4.0 recommendations, these reports were considered as ineligible for the study.
Families are ineligible for the study if any relative has tested positive for BRCA1/2 mutations.
27 There were 864 eligible offspring who did not take part in the study and 1358 ineligible for the study.
Any woman with an estimated VO2max greater than 37 mL/kg/min was ineligible for the study.
